Retrospective Analysis of Capecitabine in Routine Treatment of Advanced Triple Negative-breast Carcinoma

Objective To observe the efficacy and adverse reaction of capecitabine in routine clinical practice for unselected advanced triple negative-breast cancer(TNBC). Methods Forty-five advanced TNBC patients with capecitabine monotherapy or combined chemotherapy were collected by The Second Affiliated Hospital to Medical College of Qingdao University. The short-term efficacy, progression-free survival(PFS), and adverse reaction were analyzed retrospectively. Results Overall response rate(ORR) was 60% after 8 months of median follow-up. Response rate of combined chemotherapy group and monotherapy group was 66.7% and 33.3% respectively(P=0.028). Good performance status at baseline was a signifi cant predictor of effi cacy(P=0.005). Relapse-free interval after surgery(P=0.198) was not signifi cant predictor of PFS. The most common toxicity was hand-foot syndrome, gastrointestinal reaction and myelosuppression. Conclusion Capecitabine is a feasible, effective and well tolerated treatment for advanced TNBC. The effi cacy in real-life clinical practice is as same as results from interventional studies.